Printer Friendly

QUADRA LOGIC AUTHORIZED TO BEGIN CLINICAL TRIALS OF NEW DRUG IN CANADA

 QUADRA LOGIC AUTHORIZED
 TO BEGIN CLINICAL TRIALS OF NEW DRUG IN CANADA
 VANCOUVER, British Columbia, April 28 /PRNewswire/ -- Quadra Logic Technologies Inc. (NASDAQ-NMS: QLTIF, Toronto, Vancouver: QLT) has obtained authorization from the Canadian Health Protection Branch to begin human clinical trials of its proprietary drug, Benzoporphyrin derivative (BPD).
 First identified by researchers at Quadra Logic and the University of British Columbia, BPD is one of the few drugs ever to be both discovered and developed in Canada.
 "I am very pleased to be able to report to you today that BPD has been granted Investigational New Drug status by the Canadian Health Protection Branch," QLT President and Chief Executive Officer William J. Foran told shareholders at the company's annual general meeting.
 "QLT is now proceeding with plans to establish a clinical trial site in Canada. The disease condition for this clinical trial site will be malignant skin lesions."
 Foran said QLT has discussed the feasibility of establishing a BPD clinical trial site in Vancouver with representatives from the British Columbia Cancer Agency. Foran said QLT is confident the first Canadian clinical trials of BPD will begin at an early date.
 Dr. Harvey Lui, a clinical researcher from the Massachusetts General Hospital (MGH) in Boston and a guest speaker at the annual meeting, said preliminary results from a BPD clinical study underway at MGH, involving patients with malignant skin lesions, are encouraging and patients receiving BPD have not experienced any significant adverse reactions.
 Although BPD is currently administered to patients intravenously, QLT is also studying new formulations such as topical and oral preparations of the drug, which preclinical studies indicate may be effective in treating other disease conditions such as severe psoriasis and venereal warts.
 In other company developments, Foran said that regulatory filings for marketing approval are proceeding for PHOTOFRIN(a), QLT's first- generation photosensitive drug.
 BPD and PHOTOFRIN(a) are members of a new family of light-activated drugs that are used in photodynamic therapy, a new medical field that responds to a growing need for safer and less traumatic medical procedures that are capable of reducing hospitalization and health care costs.
 "A core goal for 1992 is to expand the clinical development of BPD and to further the development of photodynamic technology as a medical therapy with broad applications," Foran told shareholders.
 Quadra Logic Technologies Inc. is a pharmaceutical corporation engaged in the research, development and commercialization of photosensitive drugs for the treatment and prevention of disease.
 (a) PHOTOFRIN is a registered trademark.
 -0- 4/28/92
 /CONTACT: David J. Main (investors) of Quadra Logic Technologies, 604-872-7881 or 800-663-5486/
 (QLTIF) CO: Quadra Logic Technologies Inc. ST: British Columbia IN: MTC SU: PDT


DM-AL -- LA040 -- 4071 04/28/92 17:52 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 28, 1992
Words:452
Previous Article:GUY GANNETT PUBLISHING CO. SELLS FLORIDA RADIO STATIONS
Next Article:IN HOME HEALTH REPORTS RECORD EARNINGS: OPENS FIRST SATELLITE OFFICE


Related Articles
APPLE UNVEILS MACINTOSH QUADRA 950
QUADRA LOGIC BEGINS SKIN CANCER TRIALS OF NEW DRUG IN CANADA
QUADRA LOGIC BEGINS BOSTON CLINICAL TRIAL OF NEW DRUG AS A POTENTIAL TREATMENT FOR PSORIASIS
QUADRA LOGIC TECHNOLOGIES INC. ANNOUNCES RESULTS OF TESTS
QUADRA LOGIC RECEIVES CANADIAN MARKETING CLEARANCE FOR PHOTODYNAMIC THERAPY (PDT) AS NEW CANCER TREATMENT
QUADRA LOGIC TECHNOLOGIES INC. COMPLETES CDN $21.2 MILLION STOCK OFFERING
QLT RECEIVES FIRST EUROPEAN APPROVAL FOR PHOTOFRIN(R); HOLLAND APPROVAL EXPANDS USE TO LUNG AND ESOPHAGEAL CANCERS
QUADRA LOGIC RECEIVES JAPANESE APPROVAL FOR PHOTOFRIN(R)
LIGAND TO MARKET AND SELL QLT's PHOTOFRIN(R) IN CANADA
LIGAND LAUNCHES PROLEUKIN(R) IN CANADA

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters